Targeting serious diseases of
immuno-inflammation and fibrosis
Our lead product candidate cenicriviroc (CVC) is under evaluation to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis and other serious illnesses
NASH is a severe type of non-alcoholic fatty liver disease, or NAFLD. NASH affects 3 to 5 percent of the US population and can lead to life-threatening complications such as cirrhosis and liver cancer. There are no approved therapies for patients suffering from this severe condition.
Tobira is evaluating CVC’s efficacy and safety in multiple clinical studies, including the CENTAUR Study, an international, randomized Phase 2b study of CVC vs placebo in patients with NASH and liver fibrosis (NCT02217475).
CVC Development in NASH
CVC Development in Immuno-Inflammatory Diseases
- 6.23.15 Tobira Therapeutics Announces Appointment of Ian Clements as Vice President, Investor Relations and Corporate Communications
- 6.8.15 Tobira Therapeutics Completes Patient Recruitment for CENTAUR Phase 2b Study of Cenicriviroc in NASH with Liver Fibrosis
- 6.1.15 Tobira Therapeutics to Present at Upcoming Investor and Scientific Conferences in June 2015